Ligand Based Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies of Asymmetrical Hexahydro-2H-Indazole Analogs of Curcumin (AIACs) to Discover Novel Estrogen Receptors Alpha (ERα) Inhibitor

https://doi.org/10.22146/ijc.54745

Hariyanti Hariyanti(1), Kusmadi Kurmardi(2), Arry Yanuar(3), Hayun Hayun(4*)

(1) Faculty of Pharmacy and Science, Universitas Muhammadiyah Prof. DR. HAMKA, Jl. Delima II/IV, Duren Sawit, East Jakarta 13460, Indonesia
(2) Faculty of Medicine, Universitas Indonesia, UI Salemba Campus, Jl. Salemba Raya No. 6, Central Jakarta 10430, Indonesia
(3) Faculty of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia
(4) Faculty of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia
(*) Corresponding Author

Abstract


The estrogen receptor alpha (ERα) plays an important role in breast development and pro-proliferation signal activation in the normal and cancerous breast. The ERα inhibitors were potentially active as cytotoxic agents against breast cancer. This study was conducted in order to find Asymmetrical Hexahydro-2H-Indazole Analogs of Curcumin (AIACs) as hits of ERα inhibitor. A training set of 17 selected ERα inhibitors was used to create 10 pharmacophore models using LigandScout 4.2. The pharmacophore models were validated using 383 active compounds as positive data and 20674 decoys as negative data obtained from DUD.E. Model 2 was found as the best pharmacophore model and consisted of three types of pharmacophore features, viz. one hydrophobic, one hydrogen bond acceptor, and aromatic interactions. Model 2 was utilized for ligand-based virtual screening 186 of AIACs, AMACs, intermediates, and Mannich base derivative compounds. The hits obtained were further screened using molecular docking, analyzed using drug scan, and tested for its synthesis accessibility. Fourteen compounds were fulfilled as hits in pharmacophore modeling, in which 10 hits were selected by molecular docking, but only seven hits met Lipinski’s rule of five and had medium synthesis accessibility. In conclusion, seven compounds were suggested to be potentially active as ERα inhibitors and deserve to be synthesized and further investigated.


Keywords


asymmetric hexahydro-2H-indazole analogs of curcumin; AIACs; estrogen receptor alpha inhibitor; ERα inhibitor; pharmacophore modeling; molecular docking; breast cancer



References

[1] Mellatyar, H., Talaei, S., Nejati-Koshki, K., and Akbarzadeh, A., 2016, Targeting HSP90 gene expression with 17-DMAG nanoparticles in breast cancer cells, Asian Pac. J. Cancer Prev., 17 (5), 2453–2457.

[2] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A., 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68 (6), 394–424.

[3] Caldon, C.E., 2014, Estrogen signaling and the DNA damage response in hormone dependent breast cancer, Front. Oncol., 4, 1–9.

[4] Hayashi, S.I., Eguchi, H., Tanimoto, K., Yoshida, T., Omoto, Y., Inoue, A., Yoshida, N., and Yamaguchi, Y., 2003, The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application, Endocr. Relat. Cancer, 10 (2), 193–202.

[5] den Hollander, P., Savage, M.I., and Brown, P.H., 2013, Targeted therapy for breast cancer prevention. Front. Oncol., 3, 250.

[6] Revalde, J.L., Li, Y., Hawkins, B.C., Rosengren, R.J., and Paxton, J.W., 2015, Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance, Biochem. Pharmacol., 93 (3), 305–317.

[7] Yerdelen, K.O., Gul, H.I., Sakagami, H., and Umemura, N., 2015, Synthesis and biological evaluation of 1, 5-bis (4-hydroxy-3-methoxyphenyl) Penta-1, 4-dien-3-one and its aminomethyl derivatives, J. Enzyme Inhib. Med. Chem., 30 (3), 383–388.

[8] Kurnia, A., Saputri, F.C., and Hayun, H., 2019, Synthesis and anticancer potential of aminomethyl derivatives of methyl-substituted asymmetrical curcumin mono-carbonyl, J. Appl. Pharm. Sci., 9 (8), 18–24.

[9] Prasetyaningrum, P.W., Bahtiar, A., and Hayun, H., 2018, Synthesis and cytotoxicity evaluation of novel asymmetrical mono-carbonyl analogs of curcumin (AMACs) against Vero, HeLa, and MCF7 cell lines, Sci. Pharm., 86, 25.

[10] Bala, S., Sharma, N., Kajal, A., Kamboj, S., and Saini, V., 2014, Mannich bases: An important pharmacophore in present scenario, Int. J. Med. Chem., 2014, 191072.

[11] Bayomi, S.M., El-Kashef, H.A., El-Ashmawy, M.B., Nasr, M.N.A., El-Sherbeny, M.A., Badria, A., Abou-zeid, L.A., Ghaly, M.A., Abdel-Aziz, N.I., 2013, Synthesis and biological evaluation of new curcumin derivatives as antioxidant and antitumor agents, Med. Chem. Res., 22 (3), 1147–1162.

[12] Bayomi, S.M., El-Kashef, H.A.,  El-Ashmawy, M.B., Nasr, M.N.A., El-Sherbeny, M.A., Abdel-Aziz, N.I., El-Sayed, M.A.A., Suddek, G.M., El-Messery, S.M., and Ghaly, M.A., 2015, Synthesis and biological evaluation of new curcumin analogues as antioxidant and antitumor agents: Molecular modeling study, Eur. J. Med. Chem., 101, 584–594.

[13] Reddy, M.T., Rddy, V.H., Reddy R.C.K., Reddy, V.K., and Reddy, Y.V.R., 2010, Synthesis and molecular docking studies of new substituted indazole derivatives for anti-breast cancer activity, Der Pharma Chem., 6 (6), 411–417.

[14]  Plescia, S., Raffa, D., Plescia, F., Casula, G., Maggio, B., Daidone, G., Raimondi, M.V., Cusimano, M.G., Bombieri, G., and Meneghetti, F., 2010, Synthesis and biological evaluation of new indazole derivatives, ARKIVOC, 10, 163–177

[15] Shin, W.H., Zhu, X., Bures, M.G., and Kihara, D., 2015, Three-dimensional compound comparison methods and their application in drug discovery, Molecules, 20 (7), 12841–12862.

[16] Li, Q., Chen, J., Luo, S., Xu, J., Huang, Q., and Liu, T., 2015, Synthesis and assessment of the antioxidant and antitumor properties of asymmetric curcumin analogues, Eur. J. Med. Chem., 93, 461–469.

[17] Wolber, G., and Langer, T., 2005, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J. Chem. Inf. Model., 45 (1), 160–169.

[18] Seidel, T., Ibis, G., Bendix, F., and Wolber, G., 2010, Strategies for 3D pharmacophore-based virtual screening, Drug Discovery Today Technol., 7 (4), e221–e228.

[19] Kar, S., and Roy, K., 2013, How far can virtual screening take us in drug discovery?, Expert Opin. Drug Discovery, 8 (3), 245–261.

[20] Maruthanila, V.L., Elancheran, R., Roy, N.K., Bhattacharya, A., Kunnumakkara, A.B., Kabilan, S., and Kotoky, J., 2019, In silico molecular modelling of selected natural ligands and their binding features with estrogen receptor alpha, Curr. Comput. Aided Drug Des., 15 (1), 89–96.

[21] Afreen, S., Uddin, N., Mehjabin, K.Z., Niketa, T.K., Nesa, F., Akther, S.,Akther, S., Chakraborty, S., Chowdhury D., and Akther, N., 2018, In silico molecular docking approach of some selected isolated phytochemicals from Phyllanthus emblic against breast cancer, BJSTR, 10 (2), 7661–7665.

[22] Banegas Luna, A.J., Cerón-Carrasco, J.P., and Pérez-Sánchez, H., 2018, A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data, Future Med. Chem., 10 (22), 2641–2648

[23] Sun, Y., Zhou, H., Zhu, H., and Leung, S.W., 2016, Ligand-based virtual screening and inductive learning for identification of SIRT1 inhibitors in natural products, Sci. Rep., 6 (1), 19312.

[24] Liu, C., Yin, J., Yao, J., Xu, Z., Tao, Y., and Zhang, H., 2020, Pharmacophore-based virtual screening toward the discovery of novel anti-echinococcal compounds, Front. Cell. Infect. Microbiol., 10, 118.

[25] Qing, X., Lee, X.Y., De Raeymaecker, J., Tame, J., Zhang, K., De Maeyer, M., and Voet, A., 2014, Pharmacophore modeling: Advances, limitations, and current utility in drug discovery, J. Recept. Ligand Channel Res., 7, 81–92.

[26] Lone, M.Y., Manhas, A., Athar, M., and Jha, P.C., 2018, Identification of InhA inhibitors: A combination of virtual screening, molecular dynamics simulations, and quantum chemical studies, J. Biomol. Struct. Dyn., 36 (11), 2951–2965.

[27] Yuniarti, N., Mungkasi, S., Yuliani, S.H., and Istyastono, E.P., 2019, Development of a graphical user interface application to identify marginal and potent ligands for estrogen receptor alpha, Indones. J. Chem., 19 (2), 531–537.

[28] Setiawati, A., Riswanto, F.D.O., Yuliani, S.H., and Istyastono, E.P.2014, Retrospective validation of a structure-based virtual screening protocol to identify ligands for estrogen receptor alpha and its application to identify the alpha-mangostin binding pose, Indones. J. Chem., 14 (2), 103–108.

[29] Mysinger, M.M., Carchia, M., Irwin, J.J., and Shoichet, B.K., 2012, Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking, J. Med. Chem., 55 (14), 6582–6594.

[30] Kim, S., Wu, J.Y., Birzin, E.T., Frisch, K., Chan, W., Pai, L.Y., Yang, Y.T., Mosley, R.T., Fitzgerald, P.M.D., Sharma, N., Dahllund, J., Thorsell, A.G., DiNinno, F., Rohrer, S.P., Schaeffer, J.M., and Hammond, M.L., 2004, Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators, J. Med. Chem., 47 (9), 2171–2175.

[31] Doak, B.C., Over, B., Giordanetto, F., and Kihlberg, J., 2014, Oral druggable space beyond the rule of 5: Insights from drugs and clinical candidates, Chem. Biol., 21 (9), 1115–1142.

[32] Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J., 1997, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Delivery Rev., 23 (1-3), 3–25.

[33] Benet, L.Z., Hosey, C.M., Ursu, O., and Oprea, T.I., 2016, BDDCS, the rule of 5 and drugability, Adv. Drug Delivery Rev., 101, 89–98.

[34] Daina, A., Michielin, O., and Zoete, V., 2017, SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep., 7, 42717.



DOI: https://doi.org/10.22146/ijc.54745

Article Metrics

Abstract views : 1124 | views : 1013 | views : 319


Copyright (c) 2020 Indonesian Journal of Chemistry

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

 


Indonesian Journal of Chemistry (ISSN 1411-9420 / 2460-1578) - Chemistry Department, Universitas Gadjah Mada, Indonesia.

Web
Analytics View The Statistics of Indones. J. Chem.